Dabur Pharma introduces Nanoxel in India

RELATED NEWS Dabur Pharma make smart gains Dabur Pharma arrested decline in profits: Anand Rathi Have filed four ANDAs: Dabur Pharma Dabur Pharma Q2 net profit at Rs 6.96cr ALSO READ See latest News about Fresenius Kabi See previous management interviews See what other Experts & Brokerages are saying about Fresenius Kabi Fresenius Kabi BSE | NSE 13/02/12 Are Mutual Funds betting on Fresenius Kabi?

Dabur Pharma Ltd. (NSE: DABURPHARM, BSE: 532545), a leading Indian company in the field of cancer research and a manufacturer of anti cancer drugs, today announced the launch of Nanoxel - a novel drug delivery system for the widely used anti-cancer drug Paclitaxel. This nanoscale drug delivery system is India's first indigenously developed nanotechnology based chemotherapy agent.

"We are very excited to launch the first nanoparticle drug delivery system outside of the United States", said Dr. Anand Burman, Chairman, Dabur Pharma Ltd.

Dr. Rama Mukherjee, President R&D at Dabur Research Foundation (DRF) added, "The drug is a result of years of persevering research in the application of progressive technology for the treatment of various types of cancer at DRF. Owing to its water insolubility, the widely used chemotherapy agent paclitaxel that is known to have substantial anti-tumor activity is now used with a castor oil based solvent, cremophor which in turn is an agent for life threatening side effects. The anticancer drug Nanoxel, based on the principles of nanotechnology, is a cremophor free water soluble formulation - and is indicated as an effective and safe therapy for advanced breast, non-small-cell lung, and ovarian cancinomas."

With the launch of Nanoxel, Dabur Pharma expects to bring hope of better and safer therapy to a number of ailing cancer patients in India who have suffered for want of a reliable yet cost effective cancer treatment.

Contd on page 2....